Litcius/Paper detail

HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial

Xiaoxue Zhu, Yanhua Ding, Qian Wang, Guiyu Yang, Liang Zhou, Qingyu Wang

2023Investigational New Drugs11 citationsDOI

Topics & Concepts

Monoclonal antibodyOpen labelEpidermal growth factor receptorMedicineAntibodyOncologyCancer researchMonoclonalClinical trialInternal medicineReceptorPharmacologyImmunologyMonoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer ResearchPeptidase Inhibition and Analysis
HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial | Litcius